Cambridge, MA, November 09, 2021 (GLOBE NEWSWIRE) – Kernal Biologics, Inc. (Kernal Bio)–an early-development mRNA technology company to develop cancer therapies designed to improve patients’ survival and quality of life–in Berlin, Germany, at the 9th Annual International Health Conference on mRNA Compounds until tomorrow, November 10, 2021, to present results Eagerly expected from two preclinical studies. Both studies are designed to validate the power of the company’s mRNA 2.0 technology and to check the expected efficacy of its approach — bringing the company closer to its goal of conducting clinical trials next year, according to Youssef Erkol, co-founder and CEO of Kernal Bio. , MD
“We are honored to accept two of our posters at the 2021 International Health Conference, during this major year for mRNA medicine,” Dr. Erkol commented. “We are particularly excited to be in Berlin to highlight and explain our results in person – as well as online to virtual conference attendees.”
Since the conference is mixed with both in-person and virtual attendance, each poster presentation will have a taped presentation as well as the company’s experts on site for more traditional discussion/question-and-answer sessions. Cafer Ozdemir, PhD, co-founder of Kernal Bio and Director of Convergence Sciences, will provide both recorded and personalized versions of the NASA poster. Mona Draghi, PhD, director of immuno-oncology at Kernal Bio, will record the virtual presentation of the immuno-oncology poster and will be available for questions to virtual conference attendees; Dr. Erkul will be in Berlin to prepare the poster for you to attend in person.
Describing the first poster, Dr. Ercol explained, “Of course — seeing our experience in space by a NASA astronaut — it’s an adrenaline rush for the team and every adult/child scientist’s dream come true. But the study described in our poster,” taking advantage of microgravity aboard the International Space Station “Selective mRNA testing in cancer immunotherapy” had a vital goal in helping us verify that our main mRNA-based drug candidate was the right one. The study demonstrated that even under harsh microgravity conditions in space – the mRNA filter works as expected, maintaining On its strong selective properties (the ability to distinguish cancer cells from normal cells).
The second poster, “Onco-selective and Oncolytic mRNA Drives The Tumor Regression in Anti-PD1 Resistant Tumors,” features a very important study highlighting the powerful potential of the mRNA-based drug Kernal Bio for use in patients with checkpoint inhibitors, such as antiPD1/PD -L1, ineffective. While checkpoint inhibitors have been very successful in treating a variety of cancers, unfortunately, patients are often resistant or develop resistance to these drugs. This study is designed to show that the mRNA-based drug Kernal Bio can help meet this significant unmet medical need in oncology.
Commenting on the label, Dr. Ercol said: “There is a significant significant study – showing that our mRNA cocktail KR-333 triggers immune cell death of cancer cells, causing the release of immune signaling that inflames the tumor microenvironment and activates antigen-presenting cells. In English Simple – in this case, when used in combination with anti-PD1 immunotherapy, KR-333 has been shown to significantly reduce or eliminate tumors completely and improve overall survival.”
About Kernal Biologics, Inc. At KERNAL BIO, we aim to harness the power of our mRNA technology to provide cancer patients with the treatments that give them the best chance of beating their disease – while eliminating as many common side effects as possible. Our unique inside-out approach attacks diseases such as cancer at the cellular level. Our mRNA technology is engineered to move in stealth, undetected by the immune system, and is encoded to make it home in cancer cells, making it distinctively selective. Thus, we maximize the potential to improve patient outcomes compared to the existing synthetic mRNA. In addition to our work in cancer therapeutics, we also license a portion of our technology to global pharmaceutical and biotechnology companies for non-oncology applications, helping to increase funding for and funding of our in-house development programs. Please visit our new website at www.kernalbio.com and on social media: Facebook, Twitter and LinkedIn.
Contact: Caroline Grossman 781-771-5579 caroline@mirepoixllc.com
Copyright 2021 GlobeNewswire, Inc.
.
